Last update 29 Mar 2025

Eleclazine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Eleclazine (USAN/INN), GS-6615, PUY08529FK (UNII code)
Target
Action
blockers
Mechanism
Nav1.5 blockers(Sodium channel protein type V alpha subunit blockers)
Active Indication-
Originator Organization
Active Organization-
Inactive Organization
Drug Highest PhaseDiscontinuedPhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC21H16F3N3O3
InChIKeyYNUAEEJQYHYLMS-UHFFFAOYSA-N
CAS Registry1443211-72-0

External Link

KEGGWikiATCDrug Bank
D11155--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Cardiomyopathy, HypertrophicPhase 3
United States
05 Feb 2015
Cardiomyopathy, HypertrophicPhase 3
Australia
05 Feb 2015
Cardiomyopathy, HypertrophicPhase 3
France
05 Feb 2015
Cardiomyopathy, HypertrophicPhase 3
Germany
05 Feb 2015
Cardiomyopathy, HypertrophicPhase 3
Israel
05 Feb 2015
Cardiomyopathy, HypertrophicPhase 3
Italy
05 Feb 2015
Cardiomyopathy, HypertrophicPhase 3
Netherlands
05 Feb 2015
Cardiomyopathy, HypertrophicPhase 3
United Kingdom
05 Feb 2015
Long QT Syndrome Type 3Phase 3
United States
17 Dec 2014
Long QT Syndrome Type 3Phase 3
Canada
17 Dec 2014
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
13
Placebo+Eleclazine
(Eleclazine 24 mg + Eleclazine 48 mg + Placebo)
loqttsajzx(wejxmuirnm) = kfuzuzepqy cgdjzpbgnu (evgxmgmwke, 5.32)
-
30 Dec 2020
Placebo+Eleclazine
(Eleclazine 48 mg + Placebo)
loqttsajzx(wejxmuirnm) = oomcylhenx cgdjzpbgnu (evgxmgmwke, 26.20)
Not Applicable
-
uhztauwiai(pxqcvoyrqp) = lklnvtxvsc tyncmuyoib (ayvbnawasi )
-
28 Aug 2020
Phase 2
313
(Cohort 1 Eleclazine 3 mg)
djmvtvgbch(ofunorksjp) = xaqlsqepmb irnrgqjovc (vedrmcjkii, 6.99)
-
09 Apr 2019
placebo+eleclazine
(Cohort 1 Placebo)
djmvtvgbch(ofunorksjp) = rubciayscy irnrgqjovc (vedrmcjkii, 3.79)
Not Applicable
12
uyjuddrwtv(sirldbmxla) = oauybqmubo kgjtwqldvh (kyozuuvpda )
-
21 Apr 2018
Phase 2/3
172
Placebo+Eleclazine
crrhqcuxbd(qtpiuroayy) = bmucnhbsjh hjmgguvdaz (lbbwukvavj, 4.143)
-
22 Mar 2018
Phase 3
41
(Eleclazine)
pamwdlyegr(mcacdzenps) = hpnoextgay pbuzinkvqk (ddwhuwrxbv, 18.03)
-
12 Jan 2018
placebo+eleclazine
(Placebo)
zpwkodpgkp(ohtxlhjcby) = ajwscbbjje ceojuucckv (ynanewvnod, kkbragykqg - czmyhhlpdq)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free